Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
The vaccine is under FDA review
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
Subscribe To Our Newsletter & Stay Updated
